Actively Recruiting
Chemoradiotherapy in Unresectable Esophageal Cancer
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2024-12-13
105
Participants Needed
5
Research Sites
374 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This phase I/II clinical study is designed to evaluate the 1 year local tumor control rate of chemoradiotherapy using albumin-bound paclitaxel and cisplatin in unresectable esophageal squamous cell carcinomas based on Nutritional Risk Screening NRS2002.
CONDITIONS
Official Title
Chemoradiotherapy in Unresectable Esophageal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 75 years
- Pathologically or cytologically confirmed unresectable esophageal squamous cell carcinoma staged as T3N1M0-1b or T4N0-1M0-1b (AJCC 6th TNM staging, M1b limited to clavicular or celiac lymph node metastasis)
- Primary treatment performed at Cancer Hospital, Chinese Academy of Medical Sciences
- ECOG performance status score of 0 to 1
- Nutritional Risk Screening 2002 (NRS2002) score less than 3
- Estimated survival time of at least 3 months
- Normal organ and marrow function as defined by specified blood counts and chemistry levels
- Signed informed consent
You will not qualify if you...
- Presence of distant metastasis outside regional lymph nodes or involving liver, lung, bone, central nervous system, etc.
- History of other cancers within 5 years except cervical carcinoma in situ and non-malignant melanoma skin cancer
- Active infection such as active tuberculosis or hepatitis
- History of myocardial infarction within past 6 months or history of ventricular arrhythmia
- Uncontrolled illnesses including active infection, symptomatic heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness
- History of allergic reactions to paclitaxel, albumin, or cisplatin
- Participation in other clinical trials currently or within 4 weeks prior to selection
- Pregnant or breastfeeding females
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Department 4th of Radiation Oncology, Anyang Cancer Hospital
Anyang, Henan, China, 455001
Actively Recruiting
2
Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Changsha, Hunan, China, 410031
Actively Recruiting
3
Department of Radiation oncology, Jiangsu Cancer Hospital/Jiangsu Institute of Cancer Research/The affiliated Cancer Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210009
Actively Recruiting
4
Department of Radiation oncology, Jiangsu Province Hospital/The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China, 210029
Actively Recruiting
5
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
Beijing, China, 100021
Actively Recruiting
Research Team
X
Xin Wang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here